US Product Launches To Plan For In 2020
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.
You may also be interested in...
AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.
Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.
The World Health Organization is laying down the ground work to ensure that African countries at risk of an Ebola outbreak are able to approve the vaccine for use soon after it is authorized in the EU or the US.